Diclofenac Epolamine Topical System, a Generic of Flector, Now Available

Diclofenac epolamine topical system is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.

Yaral Pharma announced the launch of diclofenac epolamine topical system 1.3%, an authorized generic equivalent to Flector®.

Diclofenac epolamine is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years of age and older.

Each topical system contains 180 mg of diclofenac epolamine (13 mg per gram adhesive) in an aqueous base. When applied to intact skin, the topical system provides local analgesia by releasing diclofenac epolamine into the skin.

Like Flector, Yaral Pharma’s diclofenac epolamine topical system 1.3% offers patients a nonopioid topical treatment backed by more than 30 years of clinical experience.

The product is supplied in resealable envelopes, each containing 5 topical systems (10 cm x 14 cm) with 6 envelopes per box. The recommended dose is 1 topical system applied to the most painful area twice a day.

“Like Flector, Yaral Pharma’s diclofenac epolamine topical system 1.3% offers patients a nonopioid topical treatment backed by more than 30 years of clinical experience,” said Stephen Beckman, CEO, Yaral Pharma. “We are pleased to offer patients an accessible and affordable product that offers targeted topical pain relief and look forward to expanding our product line across a range of therapeutic areas in the months ahead.”

This article originally appeared on MPR

References:

    1. Yaral Pharma launches diclofenac epolamine topical system 1.3%. News release. Yaral Pharma. Accessed January 1, 2023. https://www.businesswire.com/news/home/20221230005209/en/Yaral-Pharma-Launches-Diclofenac-Epolamine-Topical-System-1.3.

    1. Diclofenac epolamine topical system 1.3%. Package insert. Yaral Pharma; 2023. Accessed January 3, 2022. https://www.yaral-pharma.com/dam/jcr:d80a232e-a73c-4455-9415-abfe0d11c167/Prescribing%20Information.pdf.